Profile data is unavailable for this security.
About the company
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company. It is focused on discovering and developing medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. It develops anti-cancer drugs by modifying the hyper glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize the tumor microenvironment and selectively provoke their programmed death without affecting surrounding normal tissue. Its pipeline includes VDA-1102 Ointment, VDA-1102 IV and VDA-1275. VDA-1102 ointment is a drug that selectively targets malignant cutaneous cells with minimal effects on surrounding healthy skin. VDA-1102 IV is an anti-neoplastic agent that utilizes a mechanism of action involving selective modulation of VDAC/HK2. VDA-1275 is a potent small molecule new chemical entity (NCE) with a mechanism of action that selectively modulates VDAC/HK2 interaction.
- Revenue in EUR (TTM)0.00
- Net income in EUR-1.03m
- Incorporated2021
- Employees4.00
- LocationVidac Pharma Holding PLC20-22 Wenlock RoadLONDON N1 7GUUnited KingdomGBR
- Websitehttps://vidacpharma.com/en/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| bioXXmed AG | 20.51k | -660.70k | 2.85m | 1.00 | -- | 0.1351 | -- | 139.02 | -0.1286 | -0.1286 | 0.004 | 4.11 | 0.0009 | -- | 0.4423 | 20,510.00 | -3.02 | -10.26 | -3.06 | -10.75 | -- | -- | -3,221.36 | -7,303.55 | -- | -- | 0.00 | -- | -72.60 | -32.89 | 79.56 | -- | -- | -- |
| Vidac Pharma Holding PLC | 0.00 | -1.03m | 10.18m | 4.00 | -- | -- | -- | -- | -0.0196 | -0.0196 | 0.00 | -0.0097 | 0.00 | -- | -- | -- | -562.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Biofrontera AG | 30.16m | 398.00k | 18.02m | 97.00 | 52.38 | 0.8987 | 15.08 | 0.5974 | 0.0566 | 0.0566 | 5.81 | 3.30 | 1.10 | 1.28 | 17.78 | 342,761.40 | 1.45 | -11.99 | 2.21 | -15.19 | 79.38 | 84.28 | 1.32 | -20.93 | 1.11 | 0.7511 | 0.0566 | -- | 25.30 | 8.85 | 99.16 | -- | 12.20 | -- |
| NanoRepro AG | 3.18m | -4.69m | 22.65m | 18.00 | -- | 0.5609 | -- | 7.11 | -0.3716 | -0.3716 | 0.2467 | 3.13 | 0.07 | 1.11 | 0.427 | 176,866.10 | -10.30 | 12.97 | -10.51 | 14.26 | 57.47 | 35.55 | -147.17 | 9.80 | 45.41 | -- | 0.00 | 38.44 | -91.73 | 6.65 | -25.81 | -- | -- | -- |
| B.M.P. Pharma Trading AG | 1.64k | 1.57m | 31.08m | 45.00 | 19.73 | -- | 19.80 | 18,949.04 | 0.299 | 0.299 | 0.0003 | -- | -- | -- | -- | 36.44 | -- | 16.68 | -- | 17.58 | -46.34 | 0.2347 | 95,712.20 | 87,097.18 | -- | -493.86 | -- | -- | -96.34 | -61.60 | 75.39 | 43.01 | -- | -- |
| MediGene AG | -100.00bn | -100.00bn | 37.58m | 86.00 | -- | 1.57 | -- | -- | -- | -- | -- | 0.8144 | -- | -- | -- | -- | -- | -22.31 | -- | -25.28 | -- | 90.15 | -- | -123.17 | -- | -- | 0.1228 | -- | -80.69 | -4.89 | -94.20 | -- | -8.12 | -- |
